Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Immunology and Cancer Research: Gallily Ruth


Last updated December 2021 -  Immunology and Cancer Research

List of Publications

(1) Aqawi M, Sionov RV, Gallily R, Friedman M, Steinberg D. Anti-biofilm activity of cannabigerol against streptococcus mutans. Microorg 2021;9(10).

(2) Kogan NM, Lavi Y, Topping LM, Williams RO, McCann FE, Yekhtin Z, et al. Novel cbg derivatives can reduce inflammation, pain and obesity. Molecules 2021;26(18).

(3) Aqawi M, Sionov RV, Gallily R, Friedman M, Steinberg D. Anti-Bacterial Properties of Cannabigerol Toward Streptococcus mutans. Front Microbiol 2021;12.

(4) Aqawi M, Gallily R, Sionov RV, Zaks B, Friedman M, Steinberg D. Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio harveyi. Front Microbiol 2020;11.

(5) Gallily R, Yekhtin Z. Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice. Inflammopharmacology 2019;27(1):167-173.

(6) Totary-Jain H, Sionov RV, Gallily R. Indomethacin sensitizes resistant transformed cells to macrophage cytotoxicity. Immunol Lett 2016;176:1-7.

(7) Fisher T, Golan H, Schiby G, Prichen S, Smoum R, Moshe I, et al. In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol 2016;23:S15-S22.

(8) Haj CG, Sumariwalla PF, Hanuš L, Kogan NM, Yektin Z, Mechoulam R, et al. HU-444, a novel, potent anti-inflammatory, nonpsychotropic cannabinoid. J Pharmacol Exp Ther 2015;355(1):66-75.

(9) Galanti G, Fisher T, Kventsel I, Shoham J, Gallily R, Mechoulam R, et al. Δ9-Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol 2008;47(6):1062-1070.

(10) Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 2008;54(1):244-249.

(11) Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E, et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol 2007;293(6):H3602-H3607.

(12) Quntar AAAA, Gallily R, Katzavian G, Srebnik M. Potent anti-inflammatory activity of 3-aminovinylphosphonates as inhibitors of reactive oxygen intermediates, nitric oxides generation, and tumor necrosis factor-alpha release. Eur J Pharmacol 2007;556(1-3):9-13.

(13) Kogan NM, Blázquez C, Álvarez L, Gallily R, Schlesinger M, Guzmán M, et al. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol 2006;70(1):51-59.

(14) Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006;39(2):143-151.

(15) Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 2006;103(7):2428-2433.

(16) Ben-Shabat S, Hanuš LO, Katzavian G, Gallily R. New cannabidiol derivatives: Synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J Med Chem 2006;49(3):1113-1117.

(17) Moussaieff A, Fride E, Amar Z, Lev E, Steinberg D, Gallily R, et al. The Jerusalem Balsam: From the Franciscan Monastery in the old city of Jerusalem to Martindale 33. J Ethnopharmacol 2005;101(1-3):16-26.

(18) Mechoulam R, Sumariwalla PF, Feldmann M, Gallily R. Cannabinoids in models of chronic inflammatory conditions. Phytochem Rev 2005;4(1):11-18.

(19) Goldberg S, Gallily R, Bishara S, Blumenthal EZ. Dorzolamide-induced choroidal detachment in a surgically untreated eye. Am J Ophthalmol 2004;138(2):285-286.

(20) Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A Novel Synthetic, Nonpsychoactive Cannabinoid Acid (HU-320) with Antiinflammatory Properties in Murine Collagen-Induced Arthritis. Arthritis Rheum 2004;50(3):985-998.

(21) Burstein S, Zurier RB, Sumariwalla PF, Feldmann M, Gallily R, Mechoulam R, et al. Pain reduction and lack of psychotropic effects with ajulemic acid: Comment on the article by Sumariwalla et al [4] (multiple letters). Arthritis Rheum 2004;50(12):4078-4079.

(22) Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Cannabidiol - Transdermal delivery and anti-inflammatory effect in a murine model. J Control Release 2003;93(3):377-387.

(23) Gallily R, Even-Chen T, Katzavian G, Lehmann D, Dagan A, Mechoulam R. γ-Irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 2003;44(10):1767-1773.

(24) Mechoulam R, Parker LA, Gallily R. Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol 2002;42(11 SUPPL.):11S-19S.

(25) Wohlman A, Yirmiya R, Gallily R, Weidenfeld J. Effect ofmycoplasma fermentanson brain PGE2: Role of glucocorticoids and their receptors. Neuroimmunomodulation 2001;9(3):141-147.

(26) Brenner T, Pinto F, Abramsky O, Gallily R. Inhibition of nitric oxide production for down-regulation of CNS inflammation and demyelination. Prog Brain Res 2001;132:499-506.

(27) Gallily R, Breuer A, Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice. Eur J Pharmacol 2000;406(1):R5-R7.

(28) Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000;97(17):9561-9566.

(29) Gallily R, Kipper-Galperin M, Brenner T. Mycoplasma fermentans - Induced inflammatory response of astrocytes: Selective modulation by aminoguanidine, thalidomide, pentoxifylline and IL-10. Inflammation 1999;23(6):495-505.

(30) Trembovler V, Beit-Vannai E, Younis F, Gallily R, Horowitz M, Shohami E. Antioxidants attenuate acute toxicity of tumor necrosis factor-α induced by brain injury in rat. J Interferon Cytokine Res 1999;19(7):791-795.

(31) Yirmiya R, Weidenfeld J, Barak O, Avitsur R, Pollak Y, Gallily R, et al. The role of brain cytokines in mediating the behavioral and neuroendocrine effects of intracerebral Mycoplasma fermentans. Brain Res 1999;829(1-2):28-38.

(32) Schwartz D, Engelhard D, Gallily R, Matoth I, Talma Brenner. Glial cells production of inflammatory mediators induced by streptococcus pneumoniae: Inhibition by pentoxifylline, low-molecular-weight heparin and dexamethasone. J Neurol Sci 1998;155(1):13-22.

(33) Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, Gallily R, et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 1997;186(11):1831-1841.

(34) Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, et al. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 1997;283(2):918-924.

(35) Yirmiya R, Barak O, Avitsur R, Gallily R, Weidenfeld J. Intracerebral administration of Mycoplasma fermentans produces sickness behavior: Role of prostaglandins. Brain Res 1997;749(1):71-81.

(36) Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J Neuroimmunol 1997;72(2):169-177.

(37) Engelhard D, Pomeranz S, Gallily R, Strauss N, Tuomanen E. Serotype-related differences in inflammatory response to Streptococcus pneumoniae in experimental meningitis. J Infect Dis 1997;175(4):979-982.

(38) Wohlman A, Gallily R, Yirmiya R, Weidenfeld J. Characterization of the effect of mycoplasma fermentans on the hypothalamo-pituitary-adrenal axis. Neuroendocrinology 1997;66(3):221-228.

(39) Shohami E, Bass R, Wallach D, Yamin A, Gallily R. Inhibition of tumor necrosis factor alpha (TNFα) activity in rat brain is associated with cerebroprotection after closed head injury. J Cereb Blood Flow Metab 1996;16(3):378-384.

(40) Vogt Sionov R, Gallily R. Differential H-2 antigen expression in teratocarcinoma-fibroblast hybrids. Exp Clin Immunogenet 1995;12(4):238-244.

(41) Rosendal S, Frandsen PL, Nielsen JP, Gallily R. Pasteurella multocida toxin induces IL-6, but not IL-1 alpha or TNF alpha in fibroblasts. Can J Vet Res 1995;59(2):154-156.

(42) Messika EJ, Avni O, Gallily R, Yefenof E, Baniyash M. Identification and characterization of a novel protein associated with macrophage complement receptor 3. J Immunol 1995;154(12):6563-6570.

(43) Weidenfeld J, Wohlman A, Gallily R. Mycoplasma fermentans activates the hypothalamo-pituitary adrenal axis in the rat. Neuroreport 1995;6(6):910-912.

(44) Avron A, Gallily R. Mycoplasma stimulates the production of oxidative radicals by murine peritoneal macrophages. J LEUKOCYTE BIOL 1995;57(2):264-268.

(45) Rosendal S, Levisohn S, Gallily R. Cytokines induced in vitro by Mycoplasma mycoides ssp. mycoides, large colony type. Vet Immunol Immunopathol 1995;44(3-4):269-278.

(46) Brenner T, Yamin A, Gallily R. Mycoplasma triggering of nitric oxide production by central nervous system glial cells and its inhibition by glucocorticoids. Brain Res 1994;641(1):51-56.

(47) Shohami E, Novikov M, Bass R, Yamin A, Gallily R. Closed head injury triggers early production of TNFα and IL-6 by brain tissue. J Cereb Blood Flow Metab 1994;14(4):615-619.

(48) Caplan S, Gallily R, Barenholz Y. Characterization and purification of a mycoplasma membrane-derived macrophage-activating factor. Cancer Immunol Immunother 1994;39(1):27-33.

(49) Sionov RV, Gallily R. Trophoblast protection of the inner cell mass from macrophage destruction. ADV CONTRACEPT DELIV SYST 1994;10(1-2):51-73.

(50) Brenner T, Yamin A, Abramsky O, Gallily R. Stimulation of tumor necrosis factor-α production by mycoplasmas and inhibition by dexamethasone in cultured astrocytes. Brain Res 1993;608(2):273-279.

(51) Sionov RV, Yagel S, Har-Nir R, Gallily R. Trophoblasts protect the inner cell mass from macrophage destruction. Biol Reprod 1993;49(3):588-595.

(52) Gallily R, Salman M, Tarshis M, Rottem S. Mycoplasma fermentans (incognitus strain) induces TNFα and IL-1 production by human monocytes and murine macrophages. Immunol Lett 1992;34(1):27-30.

(53) Sionov RV, Gallily R. The unique killing of embryo-derived teratocarcinoma cells by nonactivated murine macrophages is not due to a lack of H-2 antigen expression. Cell Immunol 1992;142(2):416-425.

(54) Pappo I, Bercovier H, Berry EM, Haviv Y, Gallily R, Freund HR. Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide. J PARENTER ENTER NUTR 1992;16(6):529-532.

(55) Messika E, Gallily R, Yefenof E. Radiation leukemia virus (RadLV)‐induced leukemogenesis is associated with an increased number and activity of thymic macrophages. Int J Cancer 1991;48(6):924-930.

(56) Zeira M, Gallily R, Stein I, Giloh H. Thymocyte maturation following interaction with thymus-derived macrophages. Cell Immunol 1991;134(2):370-377.

(57) Sher T, Yamin A, Rottem S, Gallily R. In vitro induction of tumor necrosis factor α, tumor cytolysis, and blast transformation by Spiroplasma membranes. J Natl Cancer Inst 1990;82(13):1142-1145.

(58) Zeira M, Gallily R. Effect of strain and age on in vitro proliferation of murine thymus-derived macrophages. Thymus 1990;15(1):1-13.

(59) Sionov RV, Gallily R. Engulfment and intracellular killing of F9 teratocarcinoma cells by non-activated murine macrophages. Int Immunol 1990;2(4):291-301.

(60) Sher T, Rottem S, Gallily R. Mycoplasma capricolum membranes induce tumor necrosis factor α by a mechanism different from that of lipopolysaccharide. Cancer Immunol Immunother 1990;31(2):86-92.

(61) Sher T, Yamin A, Matzliach M, Rottem S, Gallily R. Partial biochemical characterization of spiroplasma membrane component inducing tumor necrosis factor alpha. Anticancer Drugs 1990;1(1):83-87.

(62) Yagel S, Livni N, Zacut D, Gallily R. Characterization and localization of human placental mononuclear phagocytes by monoclonal antibodies and other cell markers. Isr J Med Sci 1990;26(5):243-249.

(63) Gifford GE, Loewenstein J, Gallily R. Production of a Factor (CIF) from Normal Fibroblast Cells Inhibiting Tumor Necrosis Factor/Cachectin Production. Proc Soc Exp Biol Med 1989;191(4):391-395.

(64) Gallily R, Sher T, Ben-Av P, Loewenstein J. Tumor necrosis factor as a mediator of Mycoplasma orale-induced tumor cell lysis by macrophages. Cell Immunol 1989;121(1):146-153.

(65) Friedman G, Chajek-Shaul T, Gallily R, Stein O, Shiloni E, Etienne J, et al. Modulation of lipoprotein lipase activity in mouse peritoneal macrophages by recombinant human tumor necrosis factor. Biochim Biophys Acta Lipids Lipid Metab 1988;963(2):201-207.

(66) Friedman G, Gallily R, Chajek-Shaul T, Stein O, Shiloni E, Etienne J, et al. Lipoprotein lipase in heart cell cultures is suppressed by bacterial lipopolysaccharide: an effect mediated by production of tumor necrosis factor. Biochim Biophys Acta Lipids Lipid Metab 1988;960(2):220-228.

(67) Zeira M, Gallily R. Interaction between thymocytes and thymus-derived macrophages. I. Surface components participating in mutual recognition. Cell Immunol 1988;117(2):264-276.

(68) Zeira M, Gallily R. Interaction between thymocytes and thymus-derived macrophages. II. Engulfment of thymocytes by macrophages. Cell Immunol 1988;117(2):277-288.

(69) Boteach D, Gallily R. Killer of virus-induced thymic lymphoma cells obtained from primary and early transfers by activated macrophages. Isr J Med Sci 1988;24(9-10):518-521.

(70) Yagel S, Palti Z, Gallily R. Prostaglandin E2-mediated suppression of human maternal lymphocyte alloreactivity by first-trimester fetal macrophages. Obstet Gynecol 1988;72(4):648-654.

(71) Loewenstein J, Yamin A, Gallily R. Establishment and characterization of murine bone marrow-derived spontaneously immortalized cell lines and clones expressing properties of normal macrophages. Exp Hematol 1987;15(6):685-694.

(72) Gallily R, Gifford GE, Loewenstein J. Suppression of both macrophage-mediated tumor cell lysis and cytolytic factor production by a factor (CIF) derived from normal embryonic fibroblasts. Cancer Immunol Immunother 1986;23(1):60-66.

(73) Gifford GE, Loewenstein J, Yamin A, Gallily R. Correlation of macrophage‐mediated tumor‐cell lysis with the production of macrophage cytolytic factor (CF). preliminary characterization of a factor inhibiting cf production. Int J Cancer 1986;37(1):73-79.

(74) Gallily R, Stain I, Zaady O. Dual effect of lectins on macrophages: Potentiation of bacterial uptake and suppression of bactericidal activity. Immunol Lett 1986;13(3):151-158.

(75) Gallily R, Stain I, Kornfeld S. Non-immune non-activated chicken macrophage destroy murine fibroblast. Dev Comp Immunol 1985;9(4):691-699.

(76) Gallily R, Zeira M, Stain I. Thymus-derived macrophages in long-term culture: Release of IL-1, stimulation of MLR and expression of tumoricidal activity. Immunology 1985;55(1):165-172.

(77) Axelrod O, Mozes E, Gallily R. Antigen presentation by proliferating thymic macrophages to a (T,G)-A-L specific T cell line in an H-2 restricted manner. Immunol Lett 1985;10(1):25-30.

(78) Cartman G, Gallily R. Lysis of primitive teratocarcinoma cells by non-activated macrophages. Immunol Lett 1985;10(3-4):207-211.

(79) Loewenstein J, Gallily R. Studies on the mechanism of macrophage-mediated tumor cell lysis induced by Mycoplasma orale. Isr J Med Sci 1984;20(9):895-897.

(80) Gallily R, Vray B, Stain I, Sharon N. Wheat germ agglutinin potentiates uptake of bacteria by murine peritoneal macrophages. Immunology 1984;52(4):679-686.

(81) Davidson S, Mansour A, Gallily R, Smolarski M, Rofolovitch M, Ginsburg H. Mast cell differentiation depends on T cells and granule synthesis on fibroblasts. Immunology 1983;48(3):439-452.

(82) Loewenstein J, Rottem S, Gallily R. Induction of macrophage-mediated cytolysis of neoplastic cells by mycoplasmas. Cell Immunol 1983;77(2):290-297.

(83) Kunin S, Gallily R. Recognition and lysis of altered-self cells by macrophages. I. Modification of target cells by 2,4,6-trinitrobenzene sulphonic acid. Immunology 1983;48(2):265-272.

(84) Gallily R, Savion N. Cultivation, proliferation and characterization of thymic macrophages. Immunology 1983;50(1):139-148.

(85) Gallily R, Cabilly S. Studies on the recognition of xenogeneic cells by nonimmune macrophages. II. Separate signals triggered cytostasis and cytolysis. Adv Exp Med Biol 1982;141:109-118.

(86) Gallily R, Yamin A, Caspi RR, Avtalion RR. Non-Immunological Recognition and Killing of Xenogeneic Cells by Macrophages: III Destruction of Fish Cells by Murine Macrophages. Top Catal 1982;6(3):569-578.

(87) Rothlein R, Gallily R, Kim YB. Development of alveolar macrophages in specific pathogen-free and germ-free Minnesota miniature swine. RES J RETICULOENDOTHEL SOC 1981;30(6):483-495.

(88) Gallily R, Stain I, Weiss DW. Mouse macrophage functions under the influence of factors released by spleen cells preincubated with the methanol extraction residue (MER) tubercle bacillus fraction. Immunopharmacology 1981;3(3):221-231.

(89) Cabilly S, Gallily R. Artificial binding of macrophages to syngeneic cells elicits cytostasis but not cytolysis. Immunology 1981;42(1):149-155.

(90) Bar-Eli M, Ehrenfeld M, Levy M, Gallily R, Eliakim M. Leukocyte chemotaxis in recurrent polyserositis (familial Mediterranean fever). Am J Med Sci 1981;281(1):15-18.

(91) Cabilly S, Gallily R. Non-immunological recognition and killing of xenogeneic cells by macrophages. I. Repertoire of recognition. Immunology 1981;44(2):347-355.

(92) Cabilly S, Gallily R. Non-immunological recognition and killing of xenogeneic cells by 0,23211 macrophages. II. Mechanism of killing. Immunology 1981;44(2):357-365.

(93) Levy M, Ehrenfeld M, Gallily R, Eliakim M. Enhanced polymorphonuclear chemotaxis - A common feature of diseases responsive to colchicine. Med Hypotheses 1981;7(1):15-20.

(94) Bar-Eli M, Ehrenfeld M, Litvin Y, Gallily R. Monocyte function in rheumatoid arthritis. Scand J Rheumatol 1980;9(1):17-23.

(95) Ehrenfeld M, Levy M, Bar Eli M, Gallily R, Eliakim M. Effect of colchicine on polymorphonuclear leucocyte chemotaxis in human volunteers. Br J Clin Pharmacol 1980;10(3):297-300.

(96) Schroit AJ, Gallily R. Macrophage fatty acid composition and phagocytosis: Effect of unsaturation on cellular phagocytic activity. Immunology 1979;36(2):199-205.

(97) Bar-Eli M, Levy M, Ehrenfeld M, Eliakim M, Gallily R. Phagocyte functions in familial Mediterranean fever. Adv Exp Med Biol 1979;121 B:341-350.

(98) Bar-Eli M, Gallily R. Age-dependent macrophage functions in New Zealand Black mice. Cell Immunol 1979;45(2):309-317.

(99) Bar-Eli M, Gallily R, Cohen HA, Wahba A. Monocyte function in psoriasis. J Invest Dermatol 1979;73(2):147-149.

(100) Gallily R, Haran-Ghera N. Macrophage functions in high and low cancer incidence strains of mice. A comparative study. Dev Comp Immunol 1979;3(C):523-536.

(101) Bercovici B, Gallily R. The cytology of the retained IUD with relation to the mechanism of action. Acta Cytol 1978;22(6):456-459.

(102) Schwartz M, Geiger B, Hooghe R, Bar-Eli M, Gallily R, Mozes E, et al. The mode of interaction with macrophages of two ordered synthetic polyeptides which differ in their thymus dependency. Immunology 1978;35(5):849-855.

(103) Wahba A, Cohen HA, Bar Eli M, Gallily R. Enhanced chemotactic and phagocytic activities of leukocytes in psoriasis vulgaris. J Invest Dermatol 1978;71(3):186-188.

(104) Bercovici B, Gallily R. The cytology of the human peritoneal fluid. Acta Cytol 1978;22(3):124-127.

(105) Schroit AJ, Gallily R. Macrophage phagocytic recognition sites. Demonstration of selectivity by hetero and alloantisera. Immunology 1977;33(1):121-127.

(106) Cabilly S, Gallily R. Studies on the recognition of xenogeneic cells by nonimmune macrophages. I. Destruction of chicken fibroblasts in vitro by murine macrophages. Cell Immunol 1977;29(1):54-65.

(107) Gallily R, Douchan Z, Weiss DW. Potentiation of mouse peritoneal macrophage antibacterial functions by treatment of the donor animals with the methanol extraction residue fraction of tubercle bacilli. Infect Immun 1977;18(2):405-411.

(108) Schroit AJ, Gallily R. Quantitative in vitro phagocytic rate measurements. J Immunol Methods 1977;17(1-2):123-130.

(109) Bar-Eli M, Gallily R, Levy M, Eliakim M. Monocyte function in familial Mediterranean fever. Am J Med Sci 1977;274(3):265-270.

(110) Gallily R. Two macrophage - affecting agents (MER and AMS). Adv Exp Med Biol 1976;73 PT-A:451-452.

(111) Schroit AJ, Rottem S, Gallily R. Motion of spin-labeled fatty acids in murine macrophages relation to cellular phagocytic activity. Biochim Biophys Acta Biomembr 1976;426(3):499-512.

(112) Gallily R, Yagel S, Weiss DW. Potentiated lysosomal enzyme, bacteriostatic and bactericidal activities of peritoneal macrophages of mice treated with MER fraction of tubercle bacilli. Adv Exp Med Biol 1976;73 PT-A:351-361.

(113) Gallily R, Eliahu H. Mechanism and specificity of macrophage-mediated cytotoxicity. Cell Immunol 1976;25(2):245-255.

(114) Schroit AJ, Kedar E, Gallily R. A rapid and sensitive technique for the detection of Fc receptors on macrophages. J Immunol Methods 1976;12(1-2):163-170.

(115) Gallily R, Bar‐Eli M. Studies on the relationships between the immunogenicity and catabolism of antigens and their binding to the surface of macrophages. Eur J Immunol 1976;6(11):789-794.

(116) Gallily R, Eliahu H, Ben-Ishay Z. Macrophage killing capacity. Aspects of mechanism. Adv Exp Med Biol 1976;66:471-476.

(117) Gallily R, Ben Ishay Z. Immune cytolysis of mouse macrophages in vitro. RES J RETICULOENDOTHEL SOC 1975;18(1):44-52.

(118) Bar Eli M, Gallily R. The effect of macrophage hydrolytic enzyme levels on the uptake and degradation of antigen and immune complexes. RES J RETICULOENDOTHEL SOC 1975;18(6):317-328.

(119) Bar-Eli M, Gallily R. Proceedings: Uptake and degradation of Ag and Ag Ab complexes by differently stimulated macrophages. Isr J Med Sci 1975;11(12):1379.

(120) Yagel S, Gallily R, Weiss DW. Effect of treatment with the MER fraction of tubercle bacilli on hydrolytic lysozomal enzyme activity of mouse peritoneal macrophages. Cell Immunol 1975;19(2):381-386.

(121) Gallily R, Zylberlicht D. Impairment of the bactericidal activity of murine macrophages following X-irradiation. Immunochemistry 1975;12(6-7):611-614.

(122) Ben-Ishay Z, Reichert F, Gallily R. Crystalline-like surface charge array of murine macrophages and lymphocytes: Visualization with cationized ferritin. J Ultrastruct Res 1975;53(1):119-127.

(123) Gallily R. Allogeneic recognition and killing capacity of immune macrophages in mixed macrophage cultures (MMC). Cell Immunol 1975;15(2):419-431.

(124) Schroit AJ, Gallily R. Studies on the binding and phagocytic inhibition properties of antimacrophage globulin (AMG). Immunology 1974;26(5):971-981.

(125) Gallily R, Eliahu H. Uptake and degradation of a polypeptide antigen by stimulated and unstimulated macrophages from responder and non responder mice. Immunology 1974;26(3):603-612.

(126) Geiger B, Gallily R. Surface morphology of irradiated macrophages. RES J RETICULOENDOTHEL SOC 1974;15(4):274-281.

(127) Gallily R, Ben-Ishay Z. Interaction between normal or irradiated macrophages and lymphocytes in mice. Cell Immunol 1974;11(1-3):314-324.

(128) Geiger B, Gallily R. Effect of X irradiation on various functions of murine macrophages. Clin Exp Immunol 1974;16(4):643-655.

(129) Schroit AJ, Geiger B, Gallily R. The capacity of macrophage components to inhibit anti‐macrophage serum activity. Eur J Immunol 1973;3(6):354-359.

(130) Gallily R. Uptake and degradation of a synthetic antigen by mouse macrophages containing different levels of lysosomal enzymes. Adv Exp Med Biol 1973;29:239-245.

(131) Geiger B, Gallily R, Gery I. The effect of irradiation on the release of lymphocyte-activating factor (LAF). Cell Immunol 1973;7(1):177-180.

(132) Gallily R, Gornostansky M. Specificity and nature of binding of antimacrophage serum. Immunology 1972;22(3):431-439.

(133) Gallily R. In vitro and in vivo studies of the properties and effects of antimacrophage sers (AMS). Clin Exp Immunol 1971;9(3):381-391.

(134) Gallily R, Aalseth B, Garvey J. A method for increasing the number of pleural macrophages in mice. Isr J Med Sci 1970;6(1):166-167.

(135) Gallily R, Garvey JS. Prolonged antibody production in rats after single injection of KLH coated on bentonite. Immunochemistry 1969;6(5):766-767.

(136) Gallily R, Garvey JS. Primary stimulation of rats and mice with hemocyanin in soluton and adsorbed on bentonite. J Immunol 1968;101(5):924-929.

(137) Gallily R, Feldman M. The role of macrophages in the induction of antibody in x-irradiated animals. Immunology 1967;12(2):197-206.

(138) Gallily R, Warwick A, Bang FB. Ontogeny of macrophage resistance to mouse hepatitis in vivo and in vitro. J Exp Med 1967;125(4):537-548.

(139) Gallily R, Feldman M. The induction of antibody production in x-irradiated animals by macrophages that interacted with antigen. Isr J Med Sci 1966;2(3):358-361.


(141) Gallily R, Shohat B, Kalish J, Gitter S, Lavie D. Further Studies on the Antitumor Effect of Cucurbitacins. Cancer Res 1962;22(9):1038-1045.

(142) Gitter S, Gallily R, Shohat B, Lavie D. Studies on the Antitumor Effect of Cucurbitacins. Cancer Res 1961;21(4):516-521.

(143) Gallily R, Woolley GW. THE HUMAN TUMOR IN THE MOUSE. Ann New York Acad Sci 1958;76(3):791-796.

(144) Sachs L, Gallily R. The chromosomes and transplantability of tumors. ii. chromosome duplication and the loss of strain specificity in solid tumors. J Natl Cancer Inst 1956;16(4):803-841.

(145) Sachs L, Gallily R. The chromosomes and transplantability of tumors. iii. the transplant-ability of mouse tumors with different ce:degrees of strain specificity into previously immunized mice. J Natl Cancer Inst 1956;16(5):1083-1097.

(146) Sachs L, Gallily R. The chromosomes and transplantability of tumors. i. fundamental chromosome numbers and strain specificity in ascites tumors. J Natl Cancer Inst 1955;15(5):1267-1289.